Specifically, the higher expression levels of CCN5 and E-cadherin in primary lesions and their lower expression levels in recurrent lesions and tissues with lymph node metastases may assist clinicians to identify patients who are at the higher risk of recurrence and metastasis. Here, CDH1 is linked to metastatic malignant neoplasm in the lymph nodes.